List of Tables
Table 1. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Competitive Situation by Manufacturers in 2025
Table 4. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Monoclonal Antibodies for Non-small Cell Lung Cancer Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Monoclonal Antibodies for Non-small Cell Lung Cancer, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Monoclonal Antibodies for Non-small Cell Lung Cancer, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Monoclonal Antibodies for Non-small Cell Lung Cancer, Product Types and Applications
Table 12. Global Key Manufacturers of Monoclonal Antibodies for Non-small Cell Lung Cancer, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Companies by Tier (Tier 1, Tier 2, Tier 3), based on Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Region (K Units), 2021–2026
Table 18. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Region (2021–2026)
Table 19. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Region (K Units), 2027–2032
Table 20. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Region (2027–2032)
Table 21. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Region (US$ Million), 2021–2026
Table 22. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Region (2021–2026)
Table 23. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Region (US$ Million), 2027–2032
Table 24. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Region (2027–2032)
Table 25. North America Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (K Units), 2021–2026
Table 27. North America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (K Units), 2027–2032
Table 28. North America Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (US$ Million), 2021–2026
Table 29. North America Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (K Units), 2021–2026
Table 32. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (K Units), 2027–2032
Table 33. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (K Units), 2021–2026
Table 42. Latin America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (K Units), 2027–2032
Table 43. Latin America Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (US$ Million), 2027–2032
Table 50. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units) by Type (2021–2026)
Table 51. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units) by Type (2027–2032)
Table 52. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Type (2021–2026)
Table 53. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Type (2027–2032)
Table 54. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Type (2021–2026)
Table 57. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Type (2027–2032)
Table 58. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Price (US$/Unit) by Type (2021–2026)
Table 59. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Price (US$/Unit) by Type (2027–2032)
Table 60. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units) by Application (2021–2026)
Table 61. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units) by Application (2027–2032)
Table 62. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Application (2021–2026)
Table 63. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Application (2027–2032)
Table 64. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Application (2021–2026)
Table 67. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Application (2027–2032)
Table 68. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Price (US$/Unit) by Application (2021–2026)
Table 69. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Price (US$/Unit) by Application (2027–2032)
Table 70. Roche Holding AG Company Information
Table 71. Roche Holding AG Description and Business Overview
Table 72. Roche Holding AG Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Roche Holding AG Monoclonal Antibodies for Non-small Cell Lung Cancer Product
Table 74. Roche Holding AG Recent Developments/Updates
Table 75. Bristol Myers Squibb Co. Company Information
Table 76. Bristol Myers Squibb Co. Description and Business Overview
Table 77. Bristol Myers Squibb Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Bristol Myers Squibb Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Product
Table 79. Bristol Myers Squibb Co. Recent Developments/Updates
Table 80. Elea Spa Company Information
Table 81. Elea Spa Description and Business Overview
Table 82. Elea Spa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Elea Spa Monoclonal Antibodies for Non-small Cell Lung Cancer Product
Table 84. Elea Spa Recent Developments/Updates
Table 85. Eli Lilly & Co. Company Information
Table 86. Eli Lilly & Co. Description and Business Overview
Table 87. Eli Lilly & Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Eli Lilly & Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Product
Table 89. Eli Lilly & Co. Recent Developments/Updates
Table 90. Merck & Co., Inc. Company Information
Table 91. Merck & Co., Inc. Description and Business Overview
Table 92. Merck & Co., Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. Merck & Co., Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Product
Table 94. Merck & Co., Inc. Recent Developments/Updates
Table 95. AstraZeneca PLC Company Information
Table 96. AstraZeneca PLC Description and Business Overview
Table 97. AstraZeneca PLC Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. AstraZeneca PLC Monoclonal Antibodies for Non-small Cell Lung Cancer Product
Table 99. AstraZeneca PLC Recent Developments/Updates
Table 100. Regeneron Pharmaceuticals, Inc. Company Information
Table 101. Regeneron Pharmaceuticals, Inc. Description and Business Overview
Table 102. Regeneron Pharmaceuticals, Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. Regeneron Pharmaceuticals, Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Product
Table 104. Regeneron Pharmaceuticals, Inc. Recent Developments/Updates
Table 105. Henlius Biopharma Co., Ltd Company Information
Table 106. Henlius Biopharma Co., Ltd Description and Business Overview
Table 107. Henlius Biopharma Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. Henlius Biopharma Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product
Table 109. Henlius Biopharma Co., Ltd Recent Developments/Updates
Table 110. Jiangsu Hengrui Medicine Co., Ltd Company Information
Table 111. Jiangsu Hengrui Medicine Co., Ltd Description and Business Overview
Table 112. Jiangsu Hengrui Medicine Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 113. Jiangsu Hengrui Medicine Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product
Table 114. Jiangsu Hengrui Medicine Co., Ltd Recent Developments/Updates
Table 115. Innovent Biologics Co., Ltd Company Information
Table 116. Innovent Biologics Co., Ltd Description and Business Overview
Table 117. Innovent Biologics Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 118. Innovent Biologics Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product
Table 119. Innovent Biologics Co., Ltd Recent Developments/Updates
Table 120. Junshi Biosciences Co., Ltd Company Information
Table 121. Junshi Biosciences Co., Ltd Description and Business Overview
Table 122. Junshi Biosciences Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 123. Junshi Biosciences Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product
Table 124. Junshi Biosciences Co., Ltd Recent Developments/Updates
Table 125. BeiGene, Ltd Company Information
Table 126. BeiGene, Ltd Description and Business Overview
Table 127. BeiGene, Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 128. BeiGene, Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product
Table 129. BeiGene, Ltd Recent Developments/Updates
Table 130. Akeso, Inc Company Information
Table 131. Akeso, Inc Description and Business Overview
Table 132. Akeso, Inc Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 133. Akeso, Inc Monoclonal Antibodies for Non-small Cell Lung Cancer Product
Table 134. Akeso, Inc Recent Developments/Updates
Table 135. Key Raw Materials Lists
Table 136. Raw Materials Key Suppliers Lists
Table 137. Monoclonal Antibodies for Non-small Cell Lung Cancer Distributors List
Table 138. Monoclonal Antibodies for Non-small Cell Lung Cancer Customers List
Table 139. Monoclonal Antibodies for Non-small Cell Lung Cancer Market Trends
Table 140. Monoclonal Antibodies for Non-small Cell Lung Cancer Market Drivers
Table 141. Monoclonal Antibodies for Non-small Cell Lung Cancer Market Challenges
Table 142. Monoclonal Antibodies for Non-small Cell Lung Cancer Market Restraints
Table 143. Research Programs/Design for This Report
Table 144. Key Data Information from Secondary Sources
Table 145. Key Data Information from Primary Sources
Table 146. Authors List of This Report
List of Figures
Figure 1. Product Picture of Monoclonal Antibodies for Non-small Cell Lung Cancer
Figure 2. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Share by Type: 2025 & 2032
Figure 4. 5 mg/mL Product Picture
Figure 5. 10 mg/mL Product Picture
Figure 6. 25 mg/mL Product Picture
Figure 7. 50 mg/mL Product Picture
Figure 8. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Value by Application (US$ Million), 2021–2032
Figure 9. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Share by Application: 2025 & 2032
Figure 10. Hospitals
Figure 11. Clinic
Figure 12. Others
Figure 13. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 14. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size (US$ Million), 2021–2032
Figure 15. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), 2021–2032
Figure 16. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Average Price (US$/Unit), 2021–2032
Figure 17. Monoclonal Antibodies for Non-small Cell Lung Cancer Report Years Considered
Figure 18. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Share by Manufacturers in 2025
Figure 19. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Share by Manufacturers in 2025
Figure 20. Top 5 and Top 10 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Players: Market Share by Revenue in Monoclonal Antibodies for Non-small Cell Lung Cancer in 2025
Figure 21. Monoclonal Antibodies for Non-small Cell Lung Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 22. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 23. North America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Country (2021–2032)
Figure 24. North America Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Country (2021–2032)
Figure 25. United States Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 26. Canada Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 27. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Country (2021–2032)
Figure 28. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Country (2021–2032)
Figure 29. Germany Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. France Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. U.K. Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Italy Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. Russia Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. Asia Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Region (2021–2032)
Figure 35. Asia Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Region (2021–2032)
Figure 36. China Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. Japan Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. South Korea Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. India Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Australia Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. China Taiwan Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Southeast Asia Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Latin America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Country (2021–2032)
Figure 44. Latin America Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Country (2021–2032)
Figure 45. Mexico Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Brazil Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Argentina Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Colombia Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Middle East and Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Country (2021–2032)
Figure 50. Middle East and Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Country (2021–2032)
Figure 51. Turkey Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Saudi Arabia Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. UAE Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. Global Sales Market Share of Monoclonal Antibodies for Non-small Cell Lung Cancer by Type (2021–2032)
Figure 55. Global Revenue Market Share of Monoclonal Antibodies for Non-small Cell Lung Cancer by Type (2021–2032)
Figure 56. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Price (US$/Unit) by Type (2021–2032)
Figure 57. Global Sales Market Share of Monoclonal Antibodies for Non-small Cell Lung Cancer by Application (2021–2032)
Figure 58. Global Revenue Market Share of Monoclonal Antibodies for Non-small Cell Lung Cancer by Application (2021–2032)
Figure 59. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Price (US$/Unit) by Application (2021–2032)
Figure 60. Monoclonal Antibodies for Non-small Cell Lung Cancer Value Chain
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
